Delandistrogene Moxeparvovec基因治疗杜氏肌营养不良:AAN指南小组证据聚焦报告
本证据聚焦系统综述了delandistrogene moxeparvovec治疗杜氏肌营养不良(DMD)的疗效与不良反应证据。共纳入6项临床试验,其中4项有同行评议数据(2项I级、2项III级),暴露数据来自134名男孩。两项I级研究均未达到主要功能运动结局,但FDA基于安全性和次要结局批准了该药。
要点
- 两项I级研究均未达到主要功能运动结局(NSAA评分变化)。
- 次要功能运动结局有改善但效应量小且未达统计学显著性。
- 需监测免疫相关副作用:心肌炎、肝损伤和血小板减少。
核心结论
- 尽管未在主要结局中显示疗效,delandistrogene moxeparvovec仍获FDA批准用于DMD男孩。
- 批准基于产品相对安全性和3期试验次要结局数据。
研究设计与样本
- 系统综述了6项临床试验,其中4项有同行评议数据(2项I级、2项III级)。
- 使用AAN 2017年治疗证据分类方案评估偏倚风险。
- 暴露数据来自134名男孩,其中128名可走动且年龄≥4至<8岁。
主要发现
- 两项I级研究均未达到主要功能运动结局(NSAA评分变化)。
- 若干次要功能运动结局在治疗组有改善,效应量小,分层分析未达统计学显著性。
- 输注后前12周治疗组皮质类固醇剂量暴露更高,可能贡献组间差异。
- 安全性结局相似,但有多项治疗相关不良事件:输注周围效应、免疫性肌炎和心肌炎、血小板减少、肝毒性。
- 一例在试验外接受治疗的患者死亡。
关键数值与推荐
- 两项I级研究未达到主要结局(NSAA评分变化)。
- 次要结局改善但未达统计学显著性。
- 不良事件包括输注周围效应、免疫性肌炎和心肌炎、血小板减少、肝毒性。
临床怎么用
- 提供者应了解该治疗的局限性。
- 需监测免疫相关副作用包括心肌炎、肝损伤和血小板减少。
- 可能需要扩展临床基础设施以支持监测。
局限性
- 主要结局未显示疗效。
- 需要额外临床试验和真实世界证据来确定短期和长期有效性及风险获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This Evidence in Focus reviews the current evidence on the efficacy and adverse effects of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) and presents clinical considerations regarding use. The author panel systematically reviewed available clinical trial data on delandistrogene moxeparvovec in patients with DMD. The risk of bias was evaluated using the American Academy of Neurology's 2017 therapeutic classification of evidence scheme. Safety information, regulatory decisions, and clinical context were also reviewed. Six clinical trials were identified, of which 4 had peer-reviewed data available. From the 4 studies with available data (2 Class I and 2 Class III), exposure data are available on 134 boys, of which 128 are ambulatory and aged ≥4 to <8 years. Both Class I studies failed to meet the primary functional motor outcome as assessed by change in the North Star Ambulatory Assessment score. Several secondary functional motor outcomes demonstrated improvement in the treatment group with small effect sizes, not meeting statistical significance from hierarchical analysis. Corticosteroid dose exposure was higher in the treatment group in the first 12 weeks after infusion, potentially contributing to measured differences between groups. Safety outcomes were similar across studies with multiple treatment-related adverse events, including peri-infusion effects, immune myositis and myocarditis, thrombocytopenia, and liver toxicity. One death has been reported in an individual who was treated with delandistrogene moxeparvovec outside of a trial. Despite not demonstrating efficacy in its primary outcome, delandistrogene moxeparvovec has been approved by the US Food and Drug Administration (FDA) for use in boys with DMD. This decision was supported by the relative safety of the product and secondary outcome measures data in the phase 3 clinical trial. As the drug may now be actively prescribed in the United States and other countries after FDA approval, providers should be aware of the limitations of the treatment and the need to monitor for immune-related side effects including myocarditis, liver injury, and thrombocytopenia, which may require expanded clinical infrastructure. Additional clinical trials and careful collection of real-world evidence from treated patients will be essential to establish short-term and long-term effectiveness and inform understanding of benefits and risks of delandistrogene moxeparvovec across the lifespan.
引用
- Oskoui M, Caller TA, Parsons JA, et al. Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee. Neurology. 2025. PMID: 40367405. doi:10.1212/WNL.0000000000213604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。